Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several administration, indication, and safety elements align with the provided XYOSTED label excerpts, but multiple statements are unsupported or potentially inaccurate relative to dosing/side-effect specifics (e.g., generic availability, pricing/coupons, and the characterization of “common” adverse effects).
Category Scores
Accurate Statements
Xyosted 100 mg is a prescription medication used for testosterone replacement therapy.
Label Indications and Usage: XYOSTED is indicated for testosterone replacement therapy in adult males for conditions associated with deficiency/absence of endogenous testosterone.
Xyosted is an injectable form of testosterone.
Drug/Dosage form in prompt: injection (single-dose autoinjector) for subcutaneous use; Label Dosage and Administration/Important Administration Instructions: subcutaneous injection.
Xyosted is administered subcutaneously.
Label Dosage and Administration: starting dose administered subcutaneously; Important Administration Instructions: XYOSTED is for subcutaneous injection in the abdominal region only.
Common side effects associated with Xyosted can include increased red blood cell count.
Label Adverse Reactions (Table examples): Hematocrit increased; Polycythemia.
Common side effects associated with Xyosted can include elevated prostate-specific antigen (PSA) levels.
Label Adverse Reactions (Table examples): PSA increased.
Common side effects associated with Xyosted can include skin reactions at the injection site.
Label Adverse Reactions (Table examples): Injection site reactions (bruising/hemorrhage/erythema).
Unsupported Statements
Without insurance, the retail price for a 30-day supply of Xyosted 100 mg can range from approximately $800 to over $1,000.
The provided XYOSTED label excerpts contain no information about retail pricing or cost ranges.
Manufacturer coupons and discount cards may be available to help reduce the out-of-pocket cost for eligible patients.
The provided XYOSTED label excerpts contain no information about coupons or discount programs.
Insurance coverage for Xyosted 100 mg varies by plan.
The provided XYOSTED label excerpts contain no insurance coverage or payer-specific statements.
If an insurance plan covers Xyosted 100 mg, the out-of-pocket cost will likely be limited to a copayment that is typically much lower than the retail price.
The provided XYOSTED label excerpts contain no cost-sharing/coplay guidance.
Some insurance plans may require prior authorization or have specific requirements for coverage of Xyosted 100 mg.
The provided XYOSTED label excerpts contain no statements about prior authorization or payer requirements.
As of now, there are no generic versions of Xyosted available.
The provided XYOSTED label excerpts contain no information about generic availability.
Common side effects associated with Xyosted can include acne.
The provided label excerpts list examples including hematocrit increase, hypertension, PSA increase, injection site reactions, headache, sleep apnea syndrome, polycythemia, depression/suicide attempts; acne is not included in the supplied adverse reaction excerpts.
Contradictions
Important Omissions
Key dosing/administration details (e.g., starting dose is 75 mg weekly in abdominal subcutaneous region; avoid intramuscular/intravascular injection; confirm hypogonadism with morning serum testosterone on at least two separate days; dose titration based on testosterone trough 350–650 ng/dL) were not stated.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While the safety-related statements about erythrocytosis (hematocrit/red blood cell count) and PSA increase align with label excerpts, several claims are unsupported (cost/coupons/generic availability/acne). Additionally, the response omits important label-mandated initiation and administration safeguards (confirming hypogonadism and injection constraints).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Includes multiple unsupported non-label claims (pricing/coupons/insurance/prior authorization/generic availability) and states acne as a common side effect without support in the provided label excerpts; also omits key label requirements for initiation and administration.
Suggested Improvement
Limit claims to what is explicitly supported by the label excerpts provided; remove or qualify unsupported economic/generic statements; ensure adverse reaction statements match label content; add label-required initiation confirmation (morning testosterone on two separate days) and administration constraints (subcutaneous abdominal region only; avoid intramuscular/intravascular; follow dose titration/monitoring).